ClinicalTrials.gg
CompletedNCT03323671Updated Dec 19, 2017

Preemptive Analgesia for Primary Dysmenorrhoea

A Phase 2/3 interventional study of preemptive mefenamic acid and mefenamic acid in Primary Dysmenorrhea, sponsored by Hanan Nabil. Completed at 1 site in Egypt. Open to female participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2017-12-19.

Sponsored by Hanan Nabil · Phase 2/3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
15 Years to 25 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies in Dysmenorrhea with a site in Egypt — 13 open to participants now, 13 under way, none of them phase 3. Dysmenorrhea · Egypt.

Enrollment
6th of 25
84 · median 58
Started
2017
with 2 others
Phase 2/3
Only one
of the 37
Registered
1st of 37
by date
Lead sponsor
1 of 37
Hanan Nabil

Among the 37 studies in Dysmenorrhea with a site in Egypt, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 2/3, and was the 1st registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

13 of the 37 studies in Dysmenorrhea with a site in Egypt are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 15 Years to 25 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Dysmenorrhea with a site in Egypt, or all of them as a file.
02

Study summary

Preemptive analgesia before the release of pain mediators

Read the detailed description

spasmodic dysmenorrhea is one of the most distressing symptoms in women. adolescents shows a usual absence from school . prostaglandin release is one of the most accepted theory responsible for spasmodic dysmenorrhea.

Non steroidal anti inflammatory Drugs were proved to be one of the alternative medications for spasmodic dysmenorrhea.

Getting the idea of what is called preemptive anesthesia by blocking the receptors before catching pain mediators the study participants will be divided randomly into 2 group group 1 receiving ttt 2 days before the anticipated menstruation and group 2 receiving ttt only during menstruation as analgesia

03

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • primary dysmenorrhea
  • preemptive analgesia
04

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • nulliparous ladies
  • with regular menstrual cycle pattern
  • those experienced history of dysmenorrhea (primary or spasmodic)
  • patients able to sallow tables

Exclusion criteria

Exclusion Criteria:

  • irregular cycles
  • any associated local causes( pelvic infection, endometriosis, fibroid or others)
  • patients with familial Mediterranean fever or other intermenstrual attacks of abdominal pain
  • gastric or duodenal ulcers or gastritis
  • other to non steroidal anti-inflammatory drugs
  • patients with severe diminution of vision or color discrimination
  • patients with any depressive or mood disorders
  • patients receiving any hormonal treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    premenstruation group

    preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle

    Drug: preemptive mefenamic acid

  • Experimental
    menstruation group

    mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle

    Drug: mefenamic acid

Interventions

06

What researchers measure

Primary outcomes

  1. change in the Degree of pain

    severity of pain according to visual pain analog scale

    Time frame: 4 months

07

Study locations

1 site
  • Mansoura University
    Mansourah, 35516, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Dec 2017, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 27, 2017
StartActual
Aug 1, 2017
Primary completionActual
Dec 1, 2017
CompletionActual
Dec 1, 2017
Last update
Dec 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03323671
Lead sponsor
Hanan Nabil
Responsible party
Hanan Nabil (Associate Professor Obstetrics and Gynecology, Mansoura University) — Sponsor-investigator
First posted
Oct 27, 2017
Start date
Aug 1, 2017
Primary completion
Dec 1, 2017
Completion
Dec 1, 2017
Last update
Dec 19, 2017

Study contacts

Hanan Nabil, MD
principal investigator · Manoura University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mefenamic Acid

Start the discussion